Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review
- PMID: 25864246
Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review
Abstract
Intrauterine devices (IUDs) provide highly effective, long-term, safe, reversible contraception, and are the most widely used reversible contraceptive method worldwide. The levonorgestrel-releasing IUD (LNG-IUD), originally designed for long-term contraceptives, is now recognized to provide non-contraceptive health benefits. These include severe dysmenorrhea and/or heavy menstrual bleeding associated with uterine myoma, endometriosis, and adenomyosis. This report aims to review the last five-year literature on the efficacy and safety of the LNG-IUD in women with dysmenorrhea. Dysmenorrhea has been reported to decrease in all women. LNG-IUD seems to be superior over copper-releasing IUD for improving dysmenorrhea. The LNG-IUD is beneficial for symptom recurrence and endometriotic cyst recurrence after conservative surgery for patients with severe pain related to endometriosis. There is also evidence to support its role in menstrual problems of severely obese adolescent females. Expulsion, one of the important factors for IUD acceptability, is rare but more common in women with distorted uterine cavity. In the treatment of dysmenorrhea, the LNG-IUD is equal or superior to treat with systemic progestins or oral contraceptives even in adolescent or menopausal women.
Similar articles
-
Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.Hum Reprod. 2015 Jul;30(7):1580-8. doi: 10.1093/humrep/dev102. Epub 2015 May 19. Hum Reprod. 2015. PMID: 25990577
-
Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.Contraception. 1995 Nov;52(5):269-76. doi: 10.1016/0010-7824(95)00210-2. Contraception. 1995. PMID: 8585882 Review.
-
A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.Drug Saf. 1996 Dec;15(6):430-40. doi: 10.2165/00002018-199615060-00006. Drug Saf. 1996. PMID: 8968696 Review.
-
An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs.Contraception. 1991 Dec;44(6):573-88. doi: 10.1016/0010-7824(91)90078-t. Contraception. 1991. PMID: 1773615 Review.
-
Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis.Contraception. 2012 Nov;86(5):458-63. doi: 10.1016/j.contraception.2012.04.001. Epub 2012 Jul 24. Contraception. 2012. PMID: 22832203
Cited by
-
Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment.Am J Obstet Gynecol. 2018 Apr;218(4):390-400. doi: 10.1016/j.ajog.2017.08.108. Epub 2017 Sep 6. Am J Obstet Gynecol. 2018. PMID: 28888592 Free PMC article. Review.
-
Efficacy of etonogestrel subcutaneous implants versus the levonorgestrel-releasing intrauterine system in the conservative treatment of adenomyosis.Open Med (Wars). 2024 Mar 21;19(1):20240914. doi: 10.1515/med-2024-0914. eCollection 2024. Open Med (Wars). 2024. PMID: 38584829 Free PMC article.
-
The Association Between Hormonal Contraceptive Use and Anemia Among Adolescent Girls and Young Women: An Analysis of Data From 51 Low- and Middle-Income Countries.J Adolesc Health. 2024 Mar;74(3):563-572. doi: 10.1016/j.jadohealth.2023.09.013. Epub 2023 Nov 18. J Adolesc Health. 2024. PMID: 37978956 Free PMC article.
-
Current and Prospective Treatment of Adenomyosis.J Clin Med. 2021 Jul 30;10(15):3410. doi: 10.3390/jcm10153410. J Clin Med. 2021. PMID: 34362193 Free PMC article. Review.
-
Endometriosis: where are we and where are we going?Reproduction. 2016 Sep;152(3):R63-78. doi: 10.1530/REP-16-0052. Epub 2016 May 10. Reproduction. 2016. PMID: 27165051 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical